Abstract: Ovarian cancer is a common gynecological malignancy. Most patients with the cancer are already at an advanced stage when visiting for medical consultations and are prone to recurrence and chemoresistance，so ovarian cancer patients have a high mortality rate and poor prognosis. N6 methyladenosine is a common epigenetic modification that dynamically and reversibly regulates the entire process of RNA metabolism. Recent studies have shown that m6A modification is aberrantly expressed in ovarian cancer patients，which is closely related to tumori⁃ genesis，metastasis and chemoresistance. Therefore，m6A can be used as a potential tumor marker for the early diagnosis or assessment of prognosis of ovarian cancer. The recent research of m6A also provides new ideas for the treatment of ovarian cancer. In this paper，we reviewed the role of m6A modification in ovarian cancer. 

Key words: ovarian cancer, m6A, therapeutic target